Chemoimmunotherapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab (MATRIx regimen) in Patients with Primary CNS Lymphoma: Results of the First Randomization of the International Extranodal Lymphoma Study Group-32 (IESLG32) Phase 2 Trial